Mostafa Faisal Mohammed Saleh: Targeting Plasma Cells to Control Persistent ADAMTS13 Autoantibodies in iTTP
Mostafa Faisal Mohammed Saleh, Associate Professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored et al., published in Hematology, adding:
“Excited to share our latest report on Daratumumab in immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Exploring the emerging role of plasma cell–targeted therapy in refractory and frequently relapsing iTTP.
Anti-CD38 therapy targets plasma cells responsible for persistent anti-ADAMTS13 autoantibody production.
Six clinical reports (approximately 40 patients): ADAMTS13 response in 75% in the largest multicenter cohort; median response time 26 days.
Promising option for refractory or relapsing iTTP, with generally manageable toxicity.
Biochemical relapse remains a concern. Prospective trials are needed to define its role.”
Title: Daratumumab in immune-mediated thrombotic thrombocytopenic purpura: emerging evidence for plasma cell–targeted therapy
Authors: Mostafa F. Mohammed Saleh, Nourah Alzaidy, Momen Nassani, Ahmed Kotb Abdrabou, Abdulrahman Nasiri, Hazza Alzahrani
Other posts featuring Mostafa Faisal on Hemostasis Today.
-
Nov 3, 2026, 16:57Ahmed Alotaibi: Which Macrophage Receptor ‘eats’ anti-E and Anti-K Coated RBCs?
-
Nov 3, 2026, 16:53Jan Sloves: Key Factors for Achieving Durable Patency in Advanced Venous Stenting
-
Nov 3, 2026, 16:45Nina Weber: Review on Kidney Injury After Stem Cell Transplantation
-
Nov 3, 2026, 16:36Chris Baugh: EMplify Podcast Explores Antithrombotic Associated Bleeding in the Emergency Department
-
Nov 3, 2026, 16:32Carlo Zaninetti: Highlights from the XXIX Congress of the Italian Society on Haemostasis and Thrombosis
-
Nov 3, 2026, 15:10Lady Joan Branson’s Story – The Hidden Danger of Hospitalization
-
Nov 3, 2026, 14:38Emna Hammami: Exploring the Haemophilia Treatment Landscape at the EHC New Technologies Conference
-
Nov 3, 2026, 14:20EHC Marks the Final Edition of Its New Technologies Conference in Bucharest
-
Nov 3, 2026, 14:15Rhiannon Morris: Awarded CASS Foundation Travel Grant to Present Research at ASH 2026